AUROBINDO PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,266 INR | +5.77% |
|
+3.90% | +16.83% |
| 03:59am | Hindalco-owned Novelis delays US IPO; shares slide | RE |
| May. 27 | Aurobindo Pharma Clocks Gains in Fiscal Q4 Consolidated Net Profit | MT |
Presentation Operator MessageOperator (Operator)Ladies and gentlemen, welcome to quarter 1 FY ...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Aurobindo Pharma specializes in the research, development, manufacturing and marketing of active pharmaceutical ingredients and generic pharmaceuticals. The group's activity is organized around 2 product families :
- generic drugs: for the treatment of neurological, cardiovascular, viral, gastroenterological, ophthalmologic and chronic diseases;
- active pharmaceutical ingredients.
At the end of March 2018, the group operated 23 production sites in India (19), the United States (3) and Brazil.
Net sales are distributed geographically as follows: India (12%), the United States (46.5%), Europe (31.2%) and other (10.3%).
Sector
Pharmaceuticals
Calendar
2024-06-06
- Investor Meeting - Bank of America
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,197
INR
Average target price
1,295
INR
Spread / Average Target
+8.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.83% | 8.4B | |
| +40.94% | 750B | |
| +34.11% | 606B | |
| -5.97% | 356B | |
| +18.34% | 326B | |
| +6.78% | 286B | |
| +18.30% | 246B | |
| -3.03% | 213B | |
| +10.89% | 213B | |
| +2.37% | 167B |
- Stock Market
- Equities
- AUROPHARMA Stock
- News Aurobindo Pharma
- Transcript : Aurobindo Pharma Limited, Q1 2023 Earnings Call, Aug 12, 2022
